Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
J Acquir Immune Defic Syndr
; 36(1): 576-87, 2004 May 01.
Article
em En
| MEDLINE
| ID: mdl-15097300
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Interleucina-2
/
Contagem de Linfócito CD4
/
Fármacos Anti-HIV
Idioma:
En
Ano de publicação:
2004
Tipo de documento:
Article